Vozmozhnosti primeneniya Fragmina pri provedenii gemodializa onkologicheskim bol'nym
- 作者: Gromova E1, Madzhuga A1, Somonova O1, Kuznetsova L1, Elizarova A1
-
隶属关系:
- ГУ РОНЦ им. Н.Н.Блохина РАМН
- 期: 卷 9, 编号 1 (2007)
- 页面: 70-74
- 栏目: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/26669
- ID: 26669
如何引用文章
全文:
详细
作者简介
E Gromova
ГУ РОНЦ им. Н.Н.Блохина РАМНОтделение реанимации и интенсивной терапии №2
A Madzhuga
ГУ РОНЦ им. Н.Н.Блохина РАМНКлиническая лаборатория
O Somonova
ГУ РОНЦ им. Н.Н.Блохина РАМНКлиническая лаборатория
L Kuznetsova
ГУ РОНЦ им. Н.Н.Блохина РАМНОтделение реанимации и интенсивной терапии №2
A Elizarova
ГУ РОНЦ им. Н.Н.Блохина РАМНКлиническая лаборатория
参考
- Ермоленко В.М. Острая почечная недостаточность. Руководство для врачей. Нефрология. Под ред. И.Е.Тареевой. М.: Медицина, 2000; 580–95.
- Bartels H. Acute renal failure. Langenbecks Arch Chir. Suppl. Kongressbd. 1997; 114: 185–7.
- Lameire N.H, Flombaum C.D, Moreau D, Ronco C. Acute renal failure in cancer patients. Ann Med 2005; 37 (1): 13–25.
- Flombaum C.D. Metabolic emergencies in the cancer patient. Semin Oncol 2000; 27 (3): 322–34.
- Jeha S. Tumor lysis syndrome. Semin Hematol 2001; 38 (4 Suppl. 10): 4–8.
- Flombaum C.D. Acute renal failure and dialysis in cancer patients. Crit Care Clin 1988; 4 (1): 61–79.
- Ozono S, Okajima E, Takashima K, Yoshida K, Hirao Y. Urological emergency for cancer patients. Gan To Kagaku Ryoho 1997; 24 (3): 292–6.
- Гельфанд Б.Р., Филимонов М.И., Бурневич С.З. Абдоминальный сепсис. Рус. мед. журн. 1998; 6: 697–706.
- Tetta C, Bellomo R, Ronco C. Artificial organ treatment for multiple organ failure, acute renal failure, and sepsis: recent new trends. Artif Organs 2003; 27 (3): 202–13.
- Hoste E.A, Kellum J.A. Acute renal failure in the critically ill: impact on morbidity and mortality. Sepsis, Kidney and Multiple Organ Disfunction. Contrib Nephrol. Eds. C.Ronco, R.Bellomo, A.Brendolan. Basel, Karger, 2004; 144: 1–11.
- Debets J.M, Kampmeijer R, van der Linden M.P et al. Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 1989; 17 (6): 489–94.
- Barriere S.L, Lowry S.F. An overview of mortality risk prediction in sepsis. Crit Care Med 1995; 23 (2): 376–93.
- Hergert-Rosental S, Uppenncamp M, Beelen D et al. Renal complications of high - dose chemotherapy and peripheral blood stem cell transplantation. Nephron 2000; 84 (2): 136–41.
- Hirasava K, Sugai T, Oda S. Acute renal failure following surgical insult. Nippon Geka Gakkai Zasshi. 1996; 97 (9): 765–70.
- Bellomo R, Angus D.C, Star R.A. The Acute Dialysis Quality Initiative. II. Patient selection for CRRT. Adv Ren Replace Ther 2002; 9: 255–9.
- Van Bommel E.F. Should continuous renal replacement therapy be used for "non - renal" indications in critically ill patients with shock? Resuscitation 1997; 33 (3): 257–70.
- Kielstein J.T, Kretschmer U, Ernst T et al. Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients: a randomized controlled study. Am J Kidney Dis 2004; 43 (2): 342–9.
- Beckley S, Wajsman L.Z, Pontes J.E et al. Intermittent hemodialysis therapy in the cancer patient. J Surg Oncol 1982; 21 (4): 261–3.
- Orlando M.P, Dillon M.E, O’Dell M.W. Heparin - induced hyperkalemia confirmed by drug rechallenge. Am J Phys Med Rehabil 2000; 79: 93–6(B).
- Schetz M. Anticoagulation in Continuous Renal Replacement Therapy. Blood Purification in Intensive Care. Contrib Nephrol. Eds. C.Ronco, R.Bellomo, G.La Greca. Basel, Karger, 2001; 132: 283–303.
- Van Wijk V, Badenhorst P.N, Luus H.G, Kotze H.E. A comparison between the use of recombinant hirudin and heparin during hemodialysis. Kidney Int 1995; 48: 1338–43 (B).
- Martin P.Y, Chevrolet J.C, Suter P, Favre H. Anticoagulation in patients treated by continuous venovenous hemofiltration: A retrospective study. Am J Kidney Dis 1994; 24: 806–12.
- Pineo J.F, Brain M.C, Gallus A.S. Tumors, mucin productions hypercoagulability. Ann NY acad Sci 1974; 230: 262–72.
- Птушкин В.В. Фрагмин в онкологии. Совр. онкол. 2004; 6 (4): 1–7.
- Бредер В.В., Горбунова В.А. Фрагмин в лечении и профилактике тромбоэмболических осложнений при онкологических заболеваниях: от теории к практике. Фарматека. 2003; 4: 1–4.
- Weitz I.C, Israel V.K, Waisman J.R et al. Chemotherapy - induced activation of hemostasis: effect of low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation. Thromb-Haemost 2002; 88: 213–20.
- Kakkar A.J, Kadziola Z, Williamson R.C.N et al. Low molecular weight heparin therapy and survival in advanced cancer. Blood 2002; 100: 148a.
- Lee A.Y, Julian J.A, Levine M.N, et al. Impact of dalteparin low molecular weight heparin (LMWH) on survival: results of a randomized trial in cancer patients with venous thromboembolism (VTE). Proc Am Soc Clin Oncol 22 2003; 846 (abstr): 211.
- Sideras K, Schaefer P.L, Okuno S.H et al. Low - molecular weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 2006; 81 (6): 758–67.
- Bick R.L. Cancer - associated thrombosis: focus on extended therapy with dalteparin. J Support Oncol 2006; 4 (3): 115–20.
- Dranitsaris G, Vincent M, Crowther M. Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis. Pharmacoeconomics 2006; 24 (6): 593–607.